In Lebanon, 2 to 3% of the population of around 3-5 million carry the 1 thalassaemia mutation.' Moreover, consanguineous marriages are found in more than 20% of the families, reaching 40% in certain communities.2 Consequently, the birth rate of infants with 13 thalassaemia major is estimated to be around 0-4/1000. The total number of living patients in Lebanon is estimated to be around 300. The recommended treatment for thalassaemia major consists of regular blood transfusions to keep the haemoglobin level above about 11 g/dl and subcutaneous infusion of the iron chelating drug desferrioxamine in a dose of 35 to 50 mg/kg/day.3 This drug costs between $6 and $12 per gram depending on the country and the method of obtaining it. The families have to pay for most of their medical treatment, and the disease therefore imposes serious financial, as well as social and psychological, burdens on the patients, their families, and the medical community at large. The present study was conducted to evaluate some aspects of these burdens, to assess the knowledge of the disease among the affected families, and to find out their attitudes to prenatal diagnosis for the condition.
SUMMARY Thalassaemia major is a relatively common disease in Lebanon. This study of 41 families with 54 patients attending the American University of Beirut Medical Center was conducted to define some aspects of the disease in Lebanon and to assess the attitudes of affected families on relevant psychosocial and economic issues. We conclude that because of the high frequency of consanguineous marriage, thalassaemia major is more common in Lebanon than might be expected on the basis of the incidence of the trait. Most patients are diagnosed early in life, but their treatment is generally far from adequate; securing desferrioxamine and paying for follow up visits to the doctor seem to be the most important financial burdens. The general population of the country is not properly informed yet and about 70% of the families had not heard about the disease before having an affected child. The inherited nature of the disease is not clear in the minds of a high percentage of the families, and in about 30% of cases the family had not been told about the advisability of screening to detect heterozygotes. The great majority of families favour a preventive approach to thalassaemia, based on heterozygote screening and the possibility of prenatal diagnosis.
In Lebanon, 2 to 3% of the population of around [3] [4] [5] million carry the 1 thalassaemia mutation.' Moreover, consanguineous marriages are found in more than 20% of the families, reaching 40% in certain communities.2 Consequently, the birth rate of infants with 13 thalassaemia major is estimated to be around 0-4/1000. The total number of living patients in Lebanon is estimated to be around 300. The recommended treatment for thalassaemia major consists of regular blood transfusions to keep the haemoglobin level above about 11 g/dl and subcutaneous infusion of the iron chelating drug desferrioxamine in a dose of 35 to 50 mg/kg/day.3 This drug costs between $6 and $12 per gram depending on the country and the method of obtaining it. The families have to pay for most of their medical treatment, and the disease therefore imposes serious financial, as well as social and psychological, burdens on the patients, their families, and the medical community at large. The present study was conducted to evaluate some aspects of these burdens, to assess the knowledge of the disease among the affected families, and to find out their attitudes to prenatal diagnosis for the condition. 
Results
The patient group included 32 males and 25 females. Table 1 gives their distribution according to their religious/ethnic community. Table 2 summarises their socioeconomic level, based on the income and occupations of the father. Table 3 gives the sibship size and birth order in the families, listed according to the mother's age, from the youngest to the oldest. It includes information on the use of contraceptives before and after the diagnosis of the first affected child and on attitudes to prenatal diagnosis.
The early age at presentation ( fig 3) generally indicates a severe form of f3 thalassaemia. Thirtyfive of the patients had had their spleen removed, mostly before the age of five years ( fig 4) . The early age at splenectomy reflects the low transfusion scheme followed in the past. Information on the level of the haematocrit at the time of transfusion could be obtained for 45 patients. Even today, only four patients were transfused in the recommended way at a haematocrit of 30% (=Hb 10 g/dl); in most the haematocrit was allowed to fall to lower levels, in many cases as low as 20% (=Hb 7 g/dl).
The families were asked to classify the financial FIG 2 burden imposed by five defined aspects of the treatment, in order from 1 (highest) to 5 (lowest). Table 4 summarises the responses in relation to social class. Only a minority of the families can obtain desferrioxamine for their children, but the attempt to do so is not determined only by social class. For most of the families who pay for the drug themselves, this is the greatest financial burden of the disease. Only eight of the 44 families had ever heard of thalassaemia before the diagnosis of their first affected child, and even now only 21 are completely clear about the inherited nature of the disease.
Twenty-six families had undergone screening for o0EEIE oS0O0000000*EEEEOO-OOOOOOEO-0OO#TEO
i : heterozygote detection, but eight had not, even though they were aware of the possibility and the indications. Nine families had not been screened and did not know it was possible. One family gave no answer.
The order of importance of certain aspects of the distress caused by the disease fell into three patterns (table 5) which varied somewhat according to socioeconomic level and access to desferrioxamine. The high ranking given to fear of early death is to be expected when desferrioxamine treatment is beyond the reach of so many families.
The answers to the following questions on social attitudes to the disease are summarised in There was no significant difference in the attitudes of the families according to their socioeconomic level. Table 7 presents the answers to the question, 'Would you request prenatal diagnosis in your next pregnancy?' according to the religious adherence of the respondents.
Discussion
Though the 44 families interviewed originated from areas all over Lebanon, 38 of them were Moslem. This is because the American University of Beirut Medical Center is located in a sector of the city that caters predominantly for the Moslem population of the country. Table 3 shows that the percentage of couples not using any contraception dropped sharply from 61% to 36% after the diagnosis of the first affected child. This change is unlikely to be related to the stage in their reproductive life, as it would be in western 
